Employers are seeking new opportunities to lower specialty drug spend and manage the rising high-costs for treatment of rare and complex conditions.

We are thrilled to bring back Dr. Robert Popovian to kick off this event to share his thought leadership and expertise in the pharmacy industry, unique insights on policy and employer strategy.

Advances in pharmacogenomics and precision medicine are leading to more targeted drug development and treatment for disease. What does this new era of personalized medicine mean for the effectiveness – and cost – of pharmaceuticals?  What ethical, legal and social challenges lie ahead?

Antonio Ciaccia believes that data – with a dash of pop culture - can light up our journey toward understanding the drug supply chain. What new knowledge can we gain, and what do we do with it? 

Biosimilars hold the promise of significant cost savings for employers and are starting to make strides in the U.S.  How can employers improve benefit design, reduce waste and increase transparency to realize greater savings?  

Moving away from the big PBMs may not be for everyone, but the pay-off can be significant for those willing to dive in. Hear from one employer who did just that and lived to tell the tale.